Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ) just unveiled an announcement.
The financial report for Shin Nippon Biomedical Laboratories, Ltd. for the nine months ending December 31, 2024, shows a revenue increase of 23.6% year-on-year, with total assets reaching ¥97,296 million. Despite the revenue growth, there was a decline in operating profit by 25.3% and ordinary profit by 15.3%. The company’s financial forecast for the fiscal year ending March 31, 2025, anticipates continued revenue growth but also projects a decrease in operating profit. This financial performance indicates a challenging period for the company, with implications for its operational strategies and stakeholder interests.
More about Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. operates in the biomedical research industry, primarily focusing on providing preclinical and clinical research services. The company is listed on the Prime Market of the Tokyo Stock Exchange.
YTD Price Performance: -0.42%
Average Trading Volume: 317,328
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: Yen69.15B
See more insights into 2395 stock on TipRanks’ Stock Analysis page.